CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade PMV Pharmaceuticals, Inc. - PMVP CFD

    2.37
    5.33%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    PMV Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 2.25
    Open* 2.19
    1-Year Change* -78.01%
    Day's Range* 2.19 - 2.38
    52 wk Range 1.18-10.48
    Average Volume (10 days) 573.91K
    Average Volume (3 months) 16.77M
    Market Cap 115.11M
    P/E Ratio -100.00K
    Shares Outstanding 51.16M
    Revenue N/A
    EPS -1.56
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date Feb 28, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 2.37 0.19 8.72% 2.18 2.38 2.18
    Nov 30, 2023 2.25 0.02 0.90% 2.23 2.38 2.23
    Nov 29, 2023 2.23 0.06 2.76% 2.17 2.38 2.17
    Nov 28, 2023 2.20 -0.02 -0.90% 2.22 2.30 2.15
    Nov 27, 2023 2.30 0.13 5.99% 2.17 2.33 2.16
    Nov 24, 2023 2.16 -0.05 -2.26% 2.21 2.26 2.15
    Nov 22, 2023 2.20 -0.04 -1.79% 2.24 2.31 2.17
    Nov 21, 2023 2.21 -0.20 -8.30% 2.41 2.42 2.20
    Nov 20, 2023 2.46 -0.02 -0.81% 2.48 2.58 2.41
    Nov 17, 2023 2.46 0.23 10.31% 2.23 2.48 2.23
    Nov 16, 2023 2.26 -0.08 -3.42% 2.34 2.37 2.17
    Nov 15, 2023 2.38 0.23 10.70% 2.15 2.45 2.14
    Nov 14, 2023 2.20 0.14 6.80% 2.06 2.38 2.04
    Nov 13, 2023 2.01 0.09 4.69% 1.92 2.10 1.91
    Nov 10, 2023 1.98 0.10 5.32% 1.88 2.03 1.83
    Nov 9, 2023 1.88 0.10 5.62% 1.78 1.99 1.78
    Nov 8, 2023 1.83 -0.29 -13.68% 2.12 2.14 1.80
    Nov 7, 2023 2.16 0.10 4.85% 2.06 2.16 1.87
    Nov 6, 2023 2.01 0.13 6.91% 1.88 2.05 1.85
    Nov 3, 2023 1.88 0.02 1.08% 1.86 2.09 1.86

    PMV Pharmaceuticals, Inc. Events

    Time (UTC) Country Event
    Wednesday, February 28, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 PMV Pharmaceuticals Inc Earnings Release
    Q4 2023 PMV Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Total Operating Expense 77.04 58.293 34.942 26.637 18.892
    Selling/General/Admin. Expenses, Total 25.052 21.8 11.009 5.878 5.039
    Research & Development 51.988 36.493 23.933 20.759 13.853
    Operating Income -77.04 -58.293 -34.942 -26.637 -18.892
    Interest Income (Expense), Net Non-Operating 3.627 0.449 0.651 1.301 1.341
    Other, Net 0.087 0.021 -0.143 -0.008 0.016
    Net Income Before Taxes -73.326 -57.823 -34.434 -25.344 -17.535
    Net Income After Taxes -73.317 -57.846 -34.44 -25.352 -17.538
    Net Income Before Extra. Items -73.317 -57.846 -34.44 -25.352 -17.538
    Net Income -73.317 -57.846 -34.44 -25.352 -17.538
    Income Available to Common Excl. Extra. Items -73.317 -57.846 -34.44 -25.352 -17.538
    Income Available to Common Incl. Extra. Items -73.317 -57.846 -34.44 -25.352 -17.538
    Diluted Net Income -73.317 -57.846 -34.44 -25.352 -17.538
    Diluted Weighted Average Shares 45.5948 45.1377 44.7778 42.9993 42.9993
    Diluted EPS Excluding Extraordinary Items -1.60801 -1.28155 -0.76913 -0.58959 -0.40787
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -1.60801 -1.28155 -0.76913 -0.58959 -0.40787
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 20.122 21.48 21.162 19.375 17.885
    Selling/General/Admin. Expenses, Total 6.279 6.407 6.137 5.709 6.423
    Research & Development 13.843 15.073 15.025 13.666 11.462
    Operating Income -20.122 -21.48 -21.162 -19.375 -17.885
    Interest Income (Expense), Net Non-Operating 2.696 2.325 1.797 1.124 0.604
    Other, Net -0.006 0.027 0.02 0.013 -0.031
    Net Income Before Taxes -17.432 -19.128 -19.345 -18.238 -17.312
    Net Income After Taxes -17.436 -19.128 -19.345 -18.229 -17.31
    Net Income Before Extra. Items -17.436 -19.128 -19.345 -18.229 -17.31
    Net Income -17.436 -19.128 -19.345 -18.229 -17.31
    Income Available to Common Excl. Extra. Items -17.436 -19.128 -19.345 -18.229 -17.31
    Income Available to Common Incl. Extra. Items -17.436 -19.128 -19.345 -18.229 -17.31
    Diluted Net Income -17.436 -19.128 -19.345 -18.229 -17.31
    Diluted Weighted Average Shares 45.8131 45.7734 45.7094 45.623 45.5711
    Diluted EPS Excluding Extraordinary Items -0.38059 -0.41789 -0.42322 -0.39956 -0.37985
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.38059 -0.41789 -0.42322 -0.39956 -0.37985
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 247.006 301.286 364.761 102.093 62.239
    Cash and Short Term Investments 241.054 297.163 361.422 101.486 61.907
    Cash & Equivalents 108.297 172.467 361.422 73.278 30.307
    Short Term Investments 132.757 124.696 0 28.208 31.6
    Prepaid Expenses 5.13 3.301 3.339 0.607 0.332
    Total Assets 270.308 331.568 365.531 103.033 63.458
    Property/Plant/Equipment, Total - Net 20.494 13.15 0.569 0.739 1.018
    Property/Plant/Equipment, Total - Gross 22.678 15.018 2.13 1.982 1.873
    Accumulated Depreciation, Total -2.184 -1.868 -1.561 -1.243 -0.855
    Other Long Term Assets, Total 0.313 0.221 0.201 0.201 0.201
    Total Current Liabilities 10.832 12.219 6.41 4.523 2.327
    Accounts Payable 2.996 3.189 1.607 2.837 1.038
    Accrued Expenses 7.836 9.03 4.803 1.686 1.289
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 24.28 23.009 6.41 4.574 2.37
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 13.448 10.79 0 0.051 0.043
    Total Equity 246.028 308.559 359.121 98.459 61.088
    Preferred Stock - Non Redeemable, Net 0 0 168.933 107.228
    Common Stock 0.00046 0.00045 0.00045 0.00043 0
    Additional Paid-In Capital 487.516 476.363 469.001 4.969 3.961
    Retained Earnings (Accumulated Deficit) -241.043 -167.726 -109.88 -75.44 -50.088
    Unrealized Gain (Loss) -0.445 -0.078 0 -0.003 -0.013
    Total Liabilities & Shareholders’ Equity 270.308 331.568 365.531 103.033 63.458
    Total Common Shares Outstanding 45.7713 45.4337 44.7778 42.9993 42.9993
    Other Equity, Total -0.00046 -0.00045 -0.00045 -0.00043
    Other Current Assets, Total 0.822 0.822
    Long Term Investments 2.495 16.911
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 205.296 190.413 233.278 247.006 265.176
    Cash and Short Term Investments 201.918 187.087 229.434 241.054 258.857
    Cash & Equivalents 52.057 68.209 142.942 108.297 99.85
    Short Term Investments 149.861 118.878 86.492 132.757 159.007
    Prepaid Expenses 2.556 2.504 3.022 5.13 5.497
    Total Assets 261.027 242.216 253.96 270.308 284.984
    Property/Plant/Equipment, Total - Net 19.367 19.865 20.368 20.494 19.501
    Property/Plant/Equipment, Total - Gross 22.278 22.589 22.722 22.678 21.609
    Accumulated Depreciation, Total -2.911 -2.724 -2.354 -2.184 -2.108
    Long Term Investments 36.184 31.757 0 2.495 0
    Other Long Term Assets, Total 0.18 0.181 0.314 0.313 0.307
    Total Current Liabilities 10.716 11.447 10.59 10.832 11.656
    Accounts Payable 1.678 3.489 1.774 2.996 4.826
    Accrued Expenses 9.038 7.958 8.816 7.836 6.83
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 23.415 24.407 23.787 24.28 23.791
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 12.699 12.96 13.197 13.448 12.135
    Total Equity 237.612 217.809 230.173 246.028 261.193
    Preferred Stock - Non Redeemable, Net
    Common Stock 0.00051 0.00046 0.00046 0.00046 0.00046
    Additional Paid-In Capital 532.214 495.744 490.46 487.516 483.916
    Retained Earnings (Accumulated Deficit) -294.247 -277.607 -260.171 -241.043 -221.698
    Unrealized Gain (Loss) -0.355 -0.328 -0.116 -0.445 -1.025
    Other Equity, Total -0.00051 -0.00046 -0.00046 -0.00046 -0.00046
    Total Liabilities & Shareholders’ Equity 261.027 242.216 253.96 270.308 284.984
    Total Common Shares Outstanding 51.1576 46.1435 45.7748 45.7713 45.6249
    Other Current Assets, Total 0.822 0.822 0.822 0.822 0.822
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -73.317 -57.846 -34.44 -25.352 -17.538
    Cash From Operating Activities -63.76 -46.571 -32.739 -22.065 -15.178
    Cash From Operating Activities 0.315 0.307 0.318 0.388 0.338
    Non-Cash Items 9.81 6.845 2.228 0.978 1.385
    Cash Taxes Paid 0 0.023 0.006 0.008 0
    Changes in Working Capital -0.568 4.123 -0.845 1.921 0.637
    Cash From Investing Activities -1.368 -143.584 27.911 3.231 21.693
    Capital Expenditures -7.984 -1.349 -0.148 -0.109 -0.452
    Other Investing Cash Flow Items, Total 6.616 -142.235 28.059 3.34 22.145
    Cash From Financing Activities 0.958 2.022 292.972 61.805 0
    Financing Cash Flow Items -0.168 0
    Issuance (Retirement) of Stock, Net 0.958 2.022 292.972 61.973 0
    Net Change in Cash -64.17 -188.133 288.144 42.971 6.515
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -19.128 -73.317 -53.972 -35.743 -18.433
    Cash From Operating Activities -15.012 -63.76 -48.436 -31.677 -17.998
    Cash From Operating Activities 0.171 0.315 0.24 0.166 0.084
    Non-Cash Items 2.13 9.81 7.205 4.913 2.314
    Cash Taxes Paid 0 0 0 0 0.002
    Changes in Working Capital 1.815 -0.568 -1.909 -1.013 -1.963
    Cash From Investing Activities 49.645 -1.368 -24.591 -54.104 -38.825
    Capital Expenditures -0.156 -7.984 -6.346 -4.296 -0.796
    Other Investing Cash Flow Items, Total 49.801 6.616 -18.245 -49.808 -38.029
    Cash From Financing Activities 0.012 0.958 0.41 0.404 0.128
    Issuance (Retirement) of Stock, Net 0.012 0.958 0.41 0.404 0.128
    Net Change in Cash 34.645 -64.17 -72.617 -85.377 -56.695
    Financing Cash Flow Items
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 13.5448 6563077 0 2023-08-23 LOW
    Boxer Capital, L.L.C. Hedge Fund 6.5294 3163795 0 2023-06-30 LOW
    Avoro Capital Advisors LLC Investment Advisor/Hedge Fund 6.3152 3060000 0 2023-06-30 LOW
    RTW Investments L.P. Investment Advisor/Hedge Fund 6.2524 3029551 30453 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 6.1121 2961610 287603 2023-06-30 LOW
    Euclidean Capital, L.L.C. Investment Advisor 5.2528 2545242 208333 2023-06-30 MED
    Verition Fund Management LLC Hedge Fund 4.8792 2364196 216845 2023-06-30 HIGH
    Citadel Advisors LLC Hedge Fund 4.3893 2126821 -132920 2023-06-30 LOW
    JP Morgan Asset Management Investment Advisor 4.2679 2067969 75254 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.1999 2035033 74082 2023-06-30 LOW
    JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 3.9485 1913218 -333 2023-06-30 LOW
    InterWest Partners Venture Capital 3.3328 1614911 0 2023-09-30 LOW
    Cowen & Co., LLC Research Firm 3.0964 1500326 1500326 2022-12-30 MED
    BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 2.8801 1395529 285351 2023-06-30 LOW
    Alkeon Capital Management LLC Investment Advisor/Hedge Fund 2.5625 1241641 73305 2023-06-30 LOW
    OUP Management Co., LLC Venture Capital 2.0416 989232 0 2023-06-30 LOW
    Principal Global Investors (Equity) Investment Advisor 1.9126 926735 8850 2023-06-30 LOW
    Federated MDTA LLC Investment Advisor/Hedge Fund 1.7353 840816 342553 2023-06-30 HIGH
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.5382 745334 79223 2023-06-30 LOW
    Woodline Partners LP Hedge Fund 1.5143 733735 557847 2023-06-30 HIGH

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    PMV Pharmaceuticals, Inc. Company profile

    About PMV Pharmaceuticals Inc

    PMV Pharmaceuticals, Inc. is a precision oncology company. PMV Pharmaceuticals, Inc. is a precision oncology company. The Company is focused on discovering and developing small molecule, tumor-agnostic therapies targeting p53 mutations. It’s lead product candidate, PC14586, is designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. The Company is also using its precision oncology platform to develop a pipeline of oral small molecule product candidates that structurally correct other p53 hotspot mutations to restore their wild-type function. Its second program, R273H, targets the p53 R273H hotspot mutation.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, PMV Pharmaceuticals Inc revenues was not reported. Net loss increased 68% to $57.8M. Higher net loss reflects Research and development increase of 52% to $35.1M (expense), General and administrative increase of 81% to $17.9M (expense), Stock-based Compensation in SGA increase from $1.1M to $3.9M (expense).

    Industry: Bio Therapeutic Drugs

    One Research Way
    PRINCETON
    NEW JERSEY 08540
    US

    Income Statement

    • Annual
    • Quarterly

    News

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    People also watch

    US100

    16,001.20 Price
    +0.470% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    Oil - Crude

    74.50 Price
    -1.560% 1D Chg, %
    Long position overnight fee -0.0136%
    Short position overnight fee -0.0083%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    Gold

    2,072.25 Price
    +1.760% 1D Chg, %
    Long position overnight fee -0.0193%
    Short position overnight fee 0.0111%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    BTC/USD

    39,631.50 Price
    +0.010% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading